Seagen Inc. (SGEN): Price and Financial Metrics


Seagen Inc. (SGEN): $139.98

-0.69 (-0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SGEN POWR Grades

  • Value is the dimension where SGEN ranks best; there it ranks ahead of 75.43% of US stocks.
  • The strongest trend for SGEN is in Growth, which has been heading down over the past 177 days.
  • SGEN's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).

SGEN Stock Summary

  • SGEN has a higher market value than 91.35% of US stocks; more precisely, its current market capitalization is $25,935,530,021.
  • For SGEN, its debt to operating expenses ratio is greater than that reported by only 7.15% of US equities we're observing.
  • With a price/sales ratio of 13.91, SEAGEN INC has a higher such ratio than 91.71% of stocks in our set.
  • Stocks that are quantitatively similar to SGEN, based on their financial statements, market capitalization, and price volatility, are BGNE, VLN, QRVO, INCY, and VERU.
  • Visit SGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.seattlegenetics.com.

SGEN Valuation Summary

  • In comparison to the median Healthcare stock, SGEN's price/earnings ratio is 268.72% lower, now standing at -38.3.
  • SGEN's price/sales ratio has moved down 67.5 over the prior 243 months.

Below are key valuation metrics over time for SGEN.

Stock Date P/S P/B P/E EV/EBIT
SGEN 2023-01-20 13.1 8.7 -38.3 -37.9
SGEN 2023-01-19 13.1 8.7 -38.5 -38.1
SGEN 2023-01-18 13.0 8.6 -38.0 -37.6
SGEN 2023-01-17 12.9 8.5 -37.9 -37.4
SGEN 2023-01-13 13.2 8.7 -38.5 -38.1
SGEN 2023-01-12 13.2 8.7 -38.5 -38.1

SGEN Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at -454.71%.
  • The year over year revenue growth rate now stands at -26.58%.
  • The year over year price growth rate now stands at -6.46%.
SGEN's revenue has moved up $1,254,321,000 over the prior 49 months.

The table below shows SGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,864.113 -657.694 -636.765
2022-06-30 1,777.873 -589.819 -739.796
2022-03-31 1,668.849 -590.493 -689.545
2021-12-31 1,574.371 -499.007 -674.471
2021-09-30 1,745.814 -26.48 -332.748
2021-06-30 2,383.485 814.141 597.266

SGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SGEN has a Quality Grade of C, ranking ahead of 74.02% of graded US stocks.
  • SGEN's asset turnover comes in at 0.44 -- ranking 102nd of 681 Pharmaceutical Products stocks.
  • BPMC, OCGN, and OTLC are the stocks whose asset turnover ratios are most correlated with SGEN.

The table below shows SGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.440 0.836 -0.133
2021-06-30 0.640 0.882 0.271
2021-03-31 0.693 0.889 0.354
2020-12-31 0.773 0.900 0.398
2020-09-30 0.788 0.910 0.374
2020-06-30 0.475 0.901 -0.184

SGEN Price Target

For more insight on analysts targets of SGEN, see our SGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $188.25 Average Broker Recommendation 1.58 (Moderate Buy)

SGEN Stock Price Chart Interactive Chart >

Price chart for SGEN

SGEN Price/Volume Stats

Current price $139.98 52-week high $183.00
Prev. close $140.67 52-week low $105.43
Day low $138.09 Volume 897,700
Day high $141.43 Avg. volume 978,889
50-day MA $129.18 Dividend yield N/A
200-day MA $144.20 Market Cap 25.99B

Seagen Inc. (SGEN) Company Bio


Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. (Source:Wikipedia)


SGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream


Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

Seagen''s Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer

The FDA has granted accelerated approval to Seagen Inc''s (NASDAQ: SGEN ) Tukysa (tucatinib) in combination with trastuzumab for colorectal cancer. The approval covers adult patients with RAS wild-type, HER2-positive unresectable, or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Tukysa is approved under the FDA''s Accelerated Approval Program … Full story available on Benzinga.com

Benzinga | January 20, 2023

FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer

On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and

US Food and Drug Administration | January 19, 2023

Seagen''s targeted cancer med Tukysa picks up accelerated FDA nod in colorectal cancer

Seagen''s targeted cancer med Tukysa picks up accelerated FDA nod in colorectal cancer esagonowsky Thu, 01/19/2023 - 15:39

FiercePharma | January 19, 2023

Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. TUKYSA is approved under the FDA’s Accelerated Approval Program based on tum

Business Wire | January 19, 2023

Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international)

Business Wire | January 19, 2023

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo 8.93%
3-mo 8.43%
6-mo -20.40%
1-year 4.07%
3-year 29.14%
5-year 149.30%
YTD 8.93%
2022 -16.88%
2021 -11.73%
2020 53.28%
2019 101.66%
2018 5.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8448 seconds.